<DOC>
	<DOCNO>NCT01544790</DOCNO>
	<brief_summary>This first randomize control trial design compare robot-assisted minimally invasive thoraco-laparoscopic esophagectomy open transthoracic esophagectomy surgical treatment resectable esophageal cancer . If hypothesis prove correct , robot-assisted minimally invasive thoraco-laparoscopic esophagectomy result low percentage postoperative complication , low blood loss , short hospital stay , least similar oncologic outcome well postoperative quality life compare open transthoracic esophagectomy ( current standard ) .</brief_summary>
	<brief_title>Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy</brief_title>
	<detailed_description>Rationale : As stated 2010 revise Dutch esophageal carcinoma guideline , golden standard surgical treatment esophageal carcinoma open transthoracic esophagectomy . Recent evidence suggest robot-assisted thoraco-laparoscopic esophagectomy use Da Vinci ® robot provide extensive resection , possibly well least equal radical ( R0 ) resection rate equal number dissect lymph node . This accompany markedly reduce blood loss reduction overall complication shorter intensive care unit ( ICU ) hospital stay . Therefore , robot-assisted thoraco-laparoscopic esophagectomy stage compare current standard care randomize control trial . Objective : Evaluate benefit , risk cost robot-assisted thoraco-laparoscopic esophagectomy alternative open transthoracic esophagectomy treatment esophageal cancer . Study design : Randomized control parallel-group superiority trial Study population : Patients ( age ≥ 18 ≤ 75 jaar ) histologically prove surgically resectable ( cT1-4a , N0-3 , M0 ) squamous cell carcinoma , adenocarcinoma undifferentiated esophageal carcinoma intrathoracic esophagus European Clinical Oncology Group ( ECOG ) status 0 , 1 2 . Intervention : 112 patient randomly allocate either A ) robot-assisted thoraco-laparoscopic esophagectomy ( n=56 ) B ) open transthoracic esophagectomy ( n=56 ) . Patients receive follow intervention : Group A. Robot-assisted thoraco-laparoscopic esophagectomy , gastric conduit formation . Group B . Open transthoracic esophagectomy , gastric conduit formation . Main study parameters/endpoints : Primary outcome percentage overall complication ( Grade 2 high ) state modified Clavien-Dindo classification ( MCDC ) . Secondary outcome individual component primary endpoint ( major minor complication ) , ( hospital ) mortality within 30 60 day , R0 resection , operation related event , postoperative recovery , oncologic outcome , cost-effectiveness quality life . Follow-up : 60 month randomization</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Histologically proven squamous cell carcinoma , adenocarcinoma undifferentiated carcinoma intrathoracic esophagus . Surgical resectable ( T14a , N03 , M0 ) Age ≥ 18 ≤ 75 year European Clinical Oncology Group ( ECOG ) performance status 0,1 2 Written inform consent Carcinoma cervical esophagus Carcinoma gastroesophageal junction ( GEJ ) major tumor gastric cardia ( Siewert III ) Prior thoracic surgery right hemithorax thorax trauma ( rationale : patient undergo open resection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Esophageal carcinoma</keyword>
	<keyword>Esophageal cancer</keyword>
	<keyword>Robotic surgery</keyword>
	<keyword>Esophagectomy</keyword>
	<keyword>Minimally invasive</keyword>
</DOC>